{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:46:10Z","timestamp":1790736370463,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejmech.2019.06.052","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T05:07:08Z","timestamp":1561180028000},"page":"257-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Sulfamates in drug design and discovery: Pre-clinical and clinical investigations"],"prefix":"10.1016","volume":"179","author":[{"given":"Seyed-Omar","family":"Zaraei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abduelmula R.","family":"Abduelkarem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan S.","family":"Anbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kobeissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miami","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Ossama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed I.","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejmech.2019.06.052_bib1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2019.06.052_bib2","first-page":"123","article-title":"The selective estrogen enzyme modulators in breast cancer: a review","volume":"1654","author":"Pasqualini","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2019.06.052_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jsbmb.2013.01.013","article-title":"Steroid derivatives as inhibitors of steroid sulfatase","volume":"137","author":"Mostafa","year":"2013","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.06.052_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1021\/jm00028a002","article-title":"Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential","volume":"37","author":"Howarth","year":"1994","journal-title":"J.\u00a0Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2019.06.052_bib5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1517\/13543776.9.8.1083","article-title":"Steroid sulfatase inhibitors","volume":"9","author":"Poirier","year":"1999","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2019.06.052_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2016.02.054","article-title":"Sulfatase inhibitors for recidivist breast cancer treatment: a chemical review","volume":"114","author":"Shah","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2019.06.052_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/JOE-11-0266","article-title":"Steroid sulfatase inhibitors for estrogen-and androgen-dependent cancers","volume":"212","author":"Purohit","year":"2012","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.ejmech.2019.06.052_bib8","series-title":"Enzymes and Their Inhibitors:drug Development","author":"Smith","year":"2004"},{"issue":"4","key":"10.1016\/j.ejmech.2019.06.052_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.maturitas.2011.09.006","article-title":"Progress in endocrine approaches to the treatment and prevention of breast cancer","volume":"70","author":"Obiorah","year":"2011","journal-title":"Maturitas"},{"issue":"36","key":"10.1016\/j.ejmech.2019.06.052_bib10","doi-asserted-by":"crossref","first-page":"11508","DOI":"10.1021\/bi00036a025","article-title":"Inactivation of sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate","volume":"34","author":"Purohit","year":"1995","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.2910630119","article-title":"In\u00a0vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate","volume":"63","author":"Purohit","year":"1995","journal-title":"Int. J. Cancer"},{"issue":"1\u20136","key":"10.1016\/j.ejmech.2019.06.052_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0960-0760(95)00087-G","article-title":"The role of cytokines and sulphatase inhibitors in regulating oestrogen synthesis in breast tumors","volume":"53","author":"Reed","year":"1995","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0960-0760(97)00018-6","article-title":"Measurement of oestrone sulphatase activity in white blood cells to monitor in\u00a0vivo inhibition of steroid sulphatase activity by oestrone-3-O-sulphamate","volume":"62","author":"Purohit","year":"1997","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2019.06.052_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0960-0760(95)00244-8","article-title":"Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism","volume":"57","author":"Woo","year":"1996","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib15","first-page":"11","article-title":"X-ray crystal structure and mechanism of action of oestrone 3-O-sulphamate, a synthetic active site-directed inhibitor of oestrone sulphatase","volume":"2","author":"Williams","year":"1996","journal-title":"Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bbrc.2004.07.108","article-title":"The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates","volume":"322","author":"Chander","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2019.06.052_bib17","series-title":"Inventors. Composition. US Patent 7335650 B2","author":"Potter","year":"2008"},{"issue":"8","key":"10.1016\/j.ejmech.2019.06.052_bib18","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.bmc.2012.03.007","article-title":"Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors","volume":"20","author":"Woo","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2019.06.052_bib19","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/cmdc.201100288","article-title":"Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495)","volume":"6","author":"Woo","year":"2011","journal-title":"ChemMedChem"},{"issue":"7","key":"10.1016\/j.ejmech.2019.06.052_bib20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1021\/jm950931z","article-title":"Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates","volume":"39","author":"Woo","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2019.06.052_bib21","first-page":"3394","article-title":"In\u00a0vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE","volume":"60","author":"Purohit","year":"2000","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ejmech.2019.06.052_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1074-5521(00)00023-5","article-title":"Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates","volume":"7","author":"Woo","year":"2000","journal-title":"Chem. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2019.06.052_bib23","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1021\/jm950931z","article-title":"Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates","volume":"39","author":"Woo","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2019.06.052_bib24","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s11095-014-1555-4","article-title":"Population pharmacokinetic modelling of Irosustat in postmenopausal women with oestrogen receptor positive breast cancer incorporating non-linear red blood cell uptake","volume":"32","author":"Parra-Guillen","year":"2015","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"11","key":"10.1016\/j.ejmech.2019.06.052_bib25","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1038\/npp.2014.115","article-title":"Genetic and pharmacological modulation of the steroid sulfatase axis improves response control; comparison with drugs used in ADHD","volume":"39","author":"Davies","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.ejmech.2019.06.052_bib26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/jm970527v","article-title":"Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase","volume":"41","author":"Woo","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2019.06.052_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1074-5521(00)00023-5","article-title":"Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates","volume":"7","author":"Woo","year":"2000","journal-title":"Chem. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2019.06.052_bib28","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.1021\/acsomega.8b01383","article-title":"C-3-and C-4-Substituted bicyclic coumarin sulfamates as potent steroid sulfatase inhibitors","volume":"3","author":"Ganeshapillai","year":"2018","journal-title":"ACS Omega"},{"issue":"24","key":"10.1016\/j.ejmech.2019.06.052_bib29","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1016\/j.bmc.2017.10.013","article-title":"Design and synthesis of p-carborane-containing sulfamates as multitarget anti-breast cancer agents","volume":"25","author":"Kaise","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.052_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0960-0760(03)00035-9","article-title":"Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate","volume":"84","author":"Suzuki","year":"2003","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.06.052_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0960-0760(03)00269-3","article-title":"The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-\u03b1 on endothelial and fibroblast cell growth, morphology and apoptosis","volume":"86","author":"Ho","year":"2003","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2019.06.052_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jsbmb.2005.01.022","article-title":"The effects of 2-methoxyoestrogen sulphamates on the in\u00a0vitro and in\u00a0vivo proliferation of breast cancer cells","volume":"94","author":"Utsumi","year":"2005","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2019.06.052_sref33","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1073\/pnas.91.9.3964","article-title":"2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib33b","first-page":"81","article-title":"Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol","volume":"57","author":"Klauber","year":"1997","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2019.06.052_bib34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1124\/mol.51.6.951","article-title":"2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression","volume":"51","author":"Yue","year":"1997","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2019.06.052_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3181\/00379727-219-44334","article-title":"Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol","volume":"219","author":"Reiser","year":"1998","journal-title":"Exp. Biol. Med."},{"issue":"6468","key":"10.1016\/j.ejmech.2019.06.052_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/368237a0","article-title":"The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth","volume":"368","author":"Fotsis","year":"1994","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.ejmech.2019.06.052_bib37","first-page":"5441","article-title":"Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells","volume":"60","author":"MacCarthy-Morrogh","year":"2000","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2019.06.052_bib38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ijc.20045","article-title":"Inhibition of in\u00a0vitro angiogenesis by 2-methoxy-and 2-ethyl-estrogen sulfamates","volume":"109","author":"Newman","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/cbt.5.1.2349","article-title":"Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors","volume":"5","author":"Dahut","year":"2006","journal-title":"Cancer Biol. Ther."},{"issue":"9","key":"10.1016\/j.ejmech.2019.06.052_bib40","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1073\/pnas.91.9.3964","article-title":"2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib41","first-page":"81","article-title":"Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol","volume":"57","author":"Klauber","year":"1997","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2019.06.052_bib42","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/sj.bjc.6601591","article-title":"Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in\u00a0vivo in rodents","volume":"90","author":"Ireson","year":"2004","journal-title":"Br. J. Canc."},{"issue":"11","key":"10.1016\/j.ejmech.2019.06.052_bib43","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/sj.bjc.6604752","article-title":"2-Methoxyoestradiol-3, 17-O, O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer","volume":"99","author":"Tagg","year":"2008","journal-title":"Br. J. Canc."},{"issue":"12","key":"10.1016\/j.ejmech.2019.06.052_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080305","article-title":"STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3 (1)\/SV40 T\/t-antigen transgenic mice","volume":"8","author":"Meyer-Losic","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejmech.2019.06.052_bib45","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0968-0896(03)00042-7","article-title":"D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase","volume":"11","author":"Fischer","year":"2003","journal-title":"Bioorg. Med. Chem."},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2019.06.052_bib46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0960-0760(03)00048-7","article-title":"Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in\u00a0vivo activity","volume":"84","author":"Fischer","year":"2003","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2019.06.052_bib47","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1535-7163.MCT-08-0195","article-title":"Anticancer sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in\u00a0vitro and in\u00a0vivo activities, molecular modeling, and protein crystallography","volume":"7","author":"Woo","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2019.06.052_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10549-007-9769-3","article-title":"Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer","volume":"111","author":"Foster","year":"2008","journal-title":"Breast Canc. Res. Treat."},{"issue":"10","key":"10.1016\/j.ejmech.2019.06.052_bib49","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.bmc.2004.02.040","article-title":"Synthesis, in\u00a0vitro and in\u00a0vivo activity of benzophenone-based inhibitors of steroid sulfatase","volume":"12","author":"Hejaz","year":"2004","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2019.06.052_bib50","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1021\/jm030926s","article-title":"Estrogenic potential of 2-alkyl-4-(thio) chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase","volume":"46","author":"Nussbaumer","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"issue":"4\u20135","key":"10.1016\/j.ejmech.2019.06.052_bib51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jsbmb.2003.12.012","article-title":"2-Phenylindole sulfamates: inhibitors of steroid sulfatase with antiproliferative activity in MCF-7 breast cancer cells","volume":"88","author":"Walter","year":"2004","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"16","key":"10.1016\/j.ejmech.2019.06.052_bib52","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0960-894X(02)00381-5","article-title":"4, 40-Benzophenone-O, O0-disulfamate: a potent inhibitor of steroid sulfatase","volume":"12","author":"Nussbaumer","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"11","key":"10.1016\/j.ejmech.2019.06.052_bib53","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/cmdc.200800164","article-title":"Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1, 2, 4-triazol-4-ylamino) benzonitrile: SAR, crystal structures, in\u00a0vitro and in\u00a0vivo activities","volume":"3","author":"Bubert","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.06.052_bib54","series-title":"Sulfamic Acid Ester Compounds Useful in the Inhibition of Steroid Sulphatase Activity and Aromatase Activity","author":"Potter","year":"2007"},{"issue":"14","key":"10.1016\/j.ejmech.2019.06.052_bib55","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1021\/jm800168s","article-title":"Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in\u00a0vitro activity","volume":"51","author":"Wood","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2019.06.052_bib56","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1021\/jm901705h","article-title":"Highly potent first examples of dual aromatase\u2212 steroid sulfatase inhibitors based on a biphenyl template","volume":"53","author":"Woo","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"issue":"4\u20135","key":"10.1016\/j.ejmech.2019.06.052_bib57","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0960-0760(02)00228-5","article-title":"Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES)","volume":"82","author":"Ahmed","year":"2002","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0006-291X(02)00444-8","article-title":"The design, synthesis, and biochemical evaluation of derivatives of biphenyl sulfamate-based compounds as novel inhibitors of estrone sulfatase","volume":"294","author":"Ahmed","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2019.06.052_bib59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jsbmb.2003.07.005","article-title":"Development of novel steroid sulfatase inhibitors: I. Synthesis and biological evaluation of biphenyl-4-O-sulfamates","volume":"87","author":"Okada","year":"2003","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2019.06.052_bib60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jsbmb.2003.11.006","article-title":"Development of novel steroid sulfatase inhibitors: II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats","volume":"88","author":"Saito","year":"2004","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2019.06.052_bib61","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0960-894X(01)00086-5","article-title":"Novel inhibitors of the enzyme estrone sulfatase (ES)","volume":"11","author":"Ahmed","year":"2001","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"6","key":"10.1016\/j.ejmech.2019.06.052_bib62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/157018007781387845","article-title":"Synthesis and in\u00a0vitro biochemical evaluation of a series of cycloalkyl esters of 4-sulfamoylated benzoic acid as inhibitors of estrone sulfatase (ES)","volume":"4","author":"Owen","year":"2007","journal-title":"Lett. Drug Des. Discov."},{"issue":"3","key":"10.1016\/j.ejmech.2019.06.052_bib63","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bmcl.2003.11.067","article-title":"Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl) oxy] benzoic acid","volume":"14","author":"Patel","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"6","key":"10.1016\/j.ejmech.2019.06.052_bib64","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/157018007781387773","article-title":"Synthesis and in\u00a0vitro bio-chemical evaluation of a series of compounds as potential inhibitors of estrone sulfatase (ES) and the role of pKa in both the synthesis and the inhibitory activity of the potential inhibitors","volume":"4","author":"Owen","year":"2007","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2019.06.052_bib65","article-title":"Benzoxa- and benzthiazoles","volume":"6716865 B1","author":"Billich","year":"2001","journal-title":"U.\u00a0S. Pat. Appl. US"},{"issue":"24","key":"10.1016\/j.ejmech.2019.06.052_bib66","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1016\/j.bmcl.2003.09.050","article-title":"6-(2-adamantan-2-ylidene-hydroxybenzoxazole)-O-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase","volume":"13","author":"Schreiner","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"3","key":"10.1016\/j.ejmech.2019.06.052_bib67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0960-0760(02)00024-9","article-title":"Nonsteroidal compounds designed to mimic potent steroid sulfatase inhibitors","volume":"80","author":"Ciobanu","year":"2002","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.06.052_bib68","series-title":"InPeptides for Youth","first-page":"219","article-title":"Synthesis of aryl sulfamate and phenol small peptide derivatives using a multidetachable sulfamate linker strategy","author":"Fournier","year":"2009"},{"issue":"12","key":"10.1016\/j.ejmech.2019.06.052_bib69","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1016\/S0968-0896(02)00306-1","article-title":"Sulfamoyloxy-substituted 2-phenylindoles: antiestrogen-based inhibitors of the steroid sulfatase in human breast cancer cells","volume":"10","author":"Golob","year":"2002","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2019.06.052_bib70","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/cmdc.201000203","article-title":"Bicyclic Derivatives of the potent dual aromatase\u2013steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4H-1, 2, 4-triazol-4-yl) amino] methyl} phenylsulfamate: synthesis, SAR, Crystal Structure, and in\u00a0vitro and in\u00a0vivo Activities","volume":"5","author":"Wood","year":"2010","journal-title":"ChemMedChem"},{"issue":"10","key":"10.1016\/j.ejmech.2019.06.052_bib71","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1248\/cpb.44.1871","article-title":"Studies on aromatase inhibitors. I. Synthesis and biological evaluation of 4-amino-4H-1,2,4-triazole derivatives","volume":"44","author":"Okada","year":"1996","journal-title":"Chem. Pharm. Bull."},{"issue":"15","key":"10.1016\/j.ejmech.2019.06.052_bib72","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1021\/jm034033b","article-title":"First dual aromatase-sulfatase inhibitors","volume":"46","author":"Woo","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2019.06.052_bib73","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1158\/1078-0432.CCR-08-1027","article-title":"A\u00a0new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor","volume":"14","author":"Foster","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.ejmech.2019.06.052_bib74","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1021\/acs.jmedchem.7b00062","article-title":"First dual inhibitors of steroid sulfatase (STS) and 17\u03b2-hydroxysteroid dehydrogenase type 1 (17\u03b2-HSD1): designed multiple ligands as novel potential therapeutics for estrogen-dependent diseases","volume":"60","author":"Salah","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2019.06.052_bib75","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1016\/j.bmc.2017.10.013","article-title":"Design and synthesis of p-carborane-containing sulfamates as multitarget anti-breast cancer agents","volume":"25","author":"Kaise","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.052_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejmech.2017.01.028","article-title":"Synthesis and biological evaluation of fluorinated N-benzoyl and N-phenylacetoyl derivatives of 3-(4-aminophenyl)-coumarin-7-O-sulfamate as steroid sulfatase inhibitors","volume":"128","author":"Da\u015bko","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib77","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/cbdd.12931","article-title":"Synthesis and biological evaluation of N-acylated tyramine sulfamates containing C\u2013F bonds as steroid sulfatase inhibitors","volume":"90","author":"Da\u015bko","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"issue":"12","key":"10.1016\/j.ejmech.2019.06.052_bib78","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1016\/j.bmc.2016.04.040","article-title":"Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors","volume":"24","author":"El-Gamal","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.052_bib79","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"2","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2019.06.052_bib80","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0960-894X(03)00029-5","article-title":"Bioorg. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates\/sulfamides with isozymes I, II and IV","volume":"13","author":"Casini","year":"2003","journal-title":"Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2019.06.052_bib81","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.bmcl.2005.03.032","article-title":"Bioorg.Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies","volume":"15","author":"De Simone","year":"2005","journal-title":"Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2019.06.052_bib82","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1747-0285.2009.00857.x","article-title":"Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates?","volume":"74","author":"De Simone","year":"2009","journal-title":"Chem. Biol. Drug Des."},{"issue":"12","key":"10.1016\/j.ejmech.2019.06.052_bib83","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.bmcl.2010.05.009","article-title":"Carbonic anhydrase inhibitors","volume":"20","author":"Supuran","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"9","key":"10.1016\/j.ejmech.2019.06.052_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108068","article-title":"Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model","volume":"9","author":"Meijer","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejmech.2019.06.052_bib85","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/14756366.2015.1069286","article-title":"Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells","volume":"31","author":"Hektoen","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2019.06.052_bib86","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1021\/jm300529u","article-title":"Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts","volume":"55","author":"Gieling","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2019.06.052_bib87","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.bmcl.2012.05.083","article-title":"Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines","volume":"22","author":"Winum","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.052_bib88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bioorg.2018.01.023","article-title":"Discovery of thiazolin-4-one-based aromatic sulfamates as a new class of carbonic anhydrase isoforms I, II, IV, and IX inhibitors","volume":"77","author":"Nocentini","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2019.06.052_bib89","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.1021\/jm5012935","article-title":"Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates","volume":"57","author":"Moeker","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"45","key":"10.1016\/j.ejmech.2019.06.052_bib90","doi-asserted-by":"crossref","first-page":"18452","DOI":"10.1021\/ja207855c","article-title":"Promiscuity of carbonic anhydrase II. Unexpected ester hydrolysis of carbohydrate-based sulfamate inhibitors","volume":"133","author":"Lopez","year":"2011","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.06.052_bib91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejmech.2014.08.051","article-title":"Sulfamates of methyl triterpenoates are effective and competitive inhibitors of carbonic anhydrase II","volume":"86","author":"Schwarz","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2019.06.052_bib92","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bmc.2010.12.048","article-title":"A\u00a0new \u03b2-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth","volume":"19","author":"Joseph","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.052_bib93","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejmech.2014.07.014","article-title":"Cyclic tertiary sulfamates: selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N-and O-substituted acesulfame derivatives","volume":"84","author":"De Monte","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2019.06.052_bib94","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1016\/j.bmc.2015.07.024","article-title":"Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties","volume":"23","author":"Congiu","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2019.06.052_bib95","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.bmcl.2018.04.038","article-title":"Synthesis, structure and bioactivity of primary sulfamate-containing natural products","volume":"28","author":"Mujumdar","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.052_bib96","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bioorg.2017.10.020","article-title":"Improving the carbonic anhydrase inhibition profile of the sulfamoylphenyl pharmacophore by attachment of carbohydrate moieties","volume":"76","author":"Riafrecha","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2019.06.052_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800209","article-title":"Novel sulfamate derivatives of menthol: synthesis, characterization, and cholinesterases and carbonic anhydrase enzymes inhibition properties","volume":"351","author":"Daryadel","year":"2018","journal-title":"Archiv. der. Pharmazie."},{"key":"10.1016\/j.ejmech.2019.06.052_bib98","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bmcl.2004.11.058","article-title":"Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic\/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates","volume":"15","author":"Winum","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"22","key":"10.1016\/j.ejmech.2019.06.052_bib99","first-page":"7634","article-title":"Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers","volume":"63","author":"Vaupel","year":"2003","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ejmech.2019.06.052_bib100","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.ejmech.2019.06.052_bib101","doi-asserted-by":"crossref","first-page":"26249","DOI":"10.3390\/ijms161125953","article-title":"Betulinyl sulfamates as anticancer agents and radiosensitizers in human breast cancer cells","volume":"16","author":"Bache","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib102","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"issue":"5","key":"10.1016\/j.ejmech.2019.06.052_bib103","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.molcel.2006.06.030","article-title":"Acyl-phosphates initiate membrane phospholipid synthesis in Gram-positive pathogens","volume":"23","author":"Lu","year":"2006","journal-title":"Mol. Cell"},{"issue":"15","key":"10.1016\/j.ejmech.2019.06.052_bib104","doi-asserted-by":"crossref","first-page":"11339","DOI":"10.1074\/jbc.M700374200","article-title":"Topology and active site of PlsY: the bacterial acylphosphate:glycerol-3-phosphate acyltransferase","volume":"282","author":"Lu","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.06.052_bib105","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cmdc.200800218","volume":"3","author":"Grimes","year":"2008","journal-title":"ChemMedChem"},{"issue":"16","key":"10.1016\/j.ejmech.2019.06.052_bib106","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1016\/j.bmc.2012.06.029","article-title":"Acyl-sulfamates target the essential glycerol-phosphate acyltransferase (PlsY) in Gram-positive bacteria","volume":"20","author":"Cherian","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.052_bib107","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1157.2000.tb02169.x","article-title":"Topiramate as an inhibitor of carbonic anhydrase isoenzymes","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ejmech.2019.06.052_bib108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/head.12480","article-title":"The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension","volume":"55","author":"Jion","year":"2015","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.ejmech.2019.06.052_bib109","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/bcp.12283","article-title":"Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review","volume":"77","author":"Dell'Orto","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.06.052_bib110","first-page":"CD010610","article-title":"Topiramate for the prophylaxis of episodic migraine in adults","volume":"6","author":"Linde","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.ejmech.2019.06.052_bib111","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, doubleblind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.ejmech.2019.06.052_bib112","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jama.291.8.965","article-title":"Topiramate for migraine prevention: a randomized controlled trial","volume":"291","author":"Brandes","year":"2004","journal-title":"J.\u00a0Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.ejmech.2019.06.052_bib113","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A\u00a0pharmacological and clinical review on topiramate, a new antiepileptic drug","volume":"35","author":"Perucca","year":"1997","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2019.06.052_bib114","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"issue":"1_suppl","key":"10.1016\/j.ejmech.2019.06.052_bib115","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1177\/0883073800015001S06","article-title":"Pharmacokinetics and pharmacodynamics of topiramate","author":"Bourgeois","year":"2000","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ejmech.2019.06.052_bib116","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-physiol-030212-183717","article-title":"Pathophysiology of migraine","volume":"75","author":"Pietrobon","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ejmech.2019.06.052_bib117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1528-1157.2000.tb02174.x","article-title":"Clinical pharmacology of topiramate: a review","volume":"41","author":"Garnett","year":"2000","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.ejmech.2019.06.052_bib118","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.ejmech.2019.06.052_bib119","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.ki.5002020","article-title":"The role of carbonic anhydrases in renal physiology","volume":"71","author":"Purkerson","year":"2007","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.ejmech.2019.06.052_bib120","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1038\/sj.bdj.2014.1054","article-title":"Salivary stones: symptoms, aetiology, biochemical composition and treatment","volume":"217","author":"Kraaij","year":"2014","journal-title":"Br. Dent. J."},{"issue":"4","key":"10.1016\/j.ejmech.2019.06.052_bib121","first-page":"161","article-title":"Modern management of obstructive salivary diseases Acta","volume":"27","author":"Capaccio","year":"2007","journal-title":"Otorhinolaryngol Ital"},{"issue":"2","key":"10.1016\/j.ejmech.2019.06.052_bib122","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0887-8994(03)00048-1","article-title":"Topiramate concentration in saliva: an alternative to serum monitoring","volume":"29","author":"Miles","year":"2003","journal-title":"Pediatr. Neurol."},{"issue":"5","key":"10.1016\/j.ejmech.2019.06.052_bib123","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gut.35.5.646","article-title":"Distribution of the carbonic anhydrase isoenzymes I, II, and VI in the human alimentary tract","volume":"35","author":"Parkkila","year":"1994","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ejmech.2019.06.052_bib124","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/41.3.8429198","article-title":"Immunoelectron microscopy of carbonic anhydrase isozyme VI in human submandibular gland: comparison with isozymes I and II","volume":"41","author":"Ogawa","year":"1993","journal-title":"J.\u00a0Histochem. Cytochem."},{"issue":"12","key":"10.1016\/j.ejmech.2019.06.052_bib125","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.joms.2016.05.011","article-title":"Possible drug-associated sialolithiasis from the bicarbonate anhydrase inhibitor topiramate: a case report and literature review","volume":"74","author":"Buhler","year":"2016","journal-title":"J.\u00a0Oral Maxillofac. Surg."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419305793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419305793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:58:08Z","timestamp":1759327088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419305793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":126,"alternative-id":["S0223523419305793"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.052","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfamates in drug design and discovery: Pre-clinical and clinical investigations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}